. 2020 Feb 3;22(5):743–754. doi: 10.1111/dom.13963

Table 2.

Key pharmacokinetic and pharmacodynamic results of second‐generation rapid‐acting insulins versus comparators in subjects with T1DM

Comparator	Administration	Faster aspart	Ultra‐rapid lispro			BioChaperone Lispro
Comparator	Administration	Aspart	Lispro	Aspart	Faster aspart	Lispro	Aspart	Faster aspart
Pharmacokinetics
Onset (t _Early50%Cmax)	sc injection	−9.5 min 52	−8.8 36 to − 12.5 43 min	−13.9 min 43	−5.9 min 43	−10.7 min ^a48	NR	NR
	CSII	−11.8 min 55	−8.6 min 40	NR	NR	NR	−11.7 min 30	−0.7 min30
Offset (t _Late50%Cmax)	sc injection	−12.2 min 52	−7.0 36 to − 13.8 43 min	−21.1 min 43	−9.5 min 43	−28.2 min ^a48	NR	NR
	CSII	−35.4 min 55	−12.2 min40	NR	NR	NR	−38.2 min 30	−19.6 min 30
Early exposure (AUC_{30 min})	sc injection	↑~2‐fold 52	↑~2.2 36 ‐ to 2.9 43 ‐fold	↑2.4‐fold 43	↑1.2‐fold 43	↑2.5 ^a43 ‐ to 2.7 49 ‐fold	NR	NR
	CSII	↑~3‐fold 55	↑1.5‐fold 40	NR	NR	NR	NR	NR
Pharmacodynamic
Onset (t _{Early50%GIRmax})	sc injection	−9.5 min 52	−12.2 min ^b35	NR	NR	−10.0 min 47
	CSII	−11.1 min 55	NR	NR	NR	NR	−13.0 min 30	+1.3 min30
Offset (t _{Late50%GIRmax})	sc injection	−14.3 min 52	0 min^b35	NR	NR	NR	NR	NR
	CSII	−24.0 min 55	NR	NR	NR	NR	−38.2 min 30	−19.6 min 30
Early effect (AUC_{GIR,30 min})	sc injection	↑~1.7‐fold 52	NR	NR	NR	↑>3‐fold 47	NR	NR
	CSII	↑~2‐fold 55	NR	NR	NR	NR	NR	NR

Table shows mean time difference versus comparators. Items in bold are statistically significant. Table adapted from oral presentation by Tim Heise at American Diabetes Association Symposium on June 25, 2018.

Abbreviations: AUC, area under the insulin concentration curve; CSII, continuous subcutaneous insulin infusion; GIR, glucose infusion rate; NR, not reported; sc, subcutaneous; t _Early50%Cmax, time to 50% of maximum insulin concentration in the early part of the pharmacokinetic profile; t _Late50%Cmax, time to late half‐maximum insulin exposure; T1DM, type 1 diabetes.

Mean data from two studies in patients with T1DM.48

In healthy subjects.